Kornimate/medical-research-clean huggingface dataset:
measurement of d-dimer levels in patients with confirmed deep vein thrombosis

Conditions: Deep Venous Thrombosis

Summary: measurement of d-di (d-dimer) levels using the in-vitro diagnostic reagent sta® - liatest® d-di and sta® - liatest® d-di plus in plasma samples from patients diagnosed with deep vein thrombosis (dvt) data from this study may be used in conjunction with data from the prospective study entitled "sta® - liatest® d-di - exclusion of venous thromboembolism (vte)", nct01221805, the diet study,


Eligibility criteria:
inclusion criteria: * the study population tested will be recruited from ambulatory outpatients (presenting at the emergency unit or outpatient clinic) suspected of having dvt. * patient is \< 80 years old. * patient presenting at least one of these symptoms indicative of proximal dvt: leg pain, tenderness (discomfort through palpation), leg swelling and /or edema, * patient has confirmed proximal dvt by imaging * low or moderate wells score * patient provides written informed consent to participate in the sample collection exclusion criteria: * patient presenting with a condition that may be associated with increased d-dimer levels, even in the absence of vte, such as: 1. fibrinolytic therapy within the previous seven (7) days, 2. bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month, 3. deep hematoma diagnosed by imaging techniques within the previous one (1) month, 4. disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment), 5. sepsis, severe infections, pneumonia within the previous 1 month, 6. known liver cirrhosis, 7. pregnancy or post-partum within the previous 1 month, 8. atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage iii or iv), 9. sickle cell disease, * patients presenting with a suspect thrombotic event related to catheter implantation * ongoing therapeutic anticoagulants (curative and preventive treatment) starting twenty four (24) hours or more before the blood drawing for d-dimer testing

Keywords: d-dimer dvt wells score
intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy

Conditions: Anal Cancer

Summary: a commercially available vaginal dilator set will be used as measuring device. the grading of vaginal stenosis will be determined as difference of the diameter of vaginal dilator to the baseline. a reduction of the diameter of \ 35-49% as grade 3 and a reduction \>/=50% as grade 4. the investigators hypothesize that the rate of vaginal stenosis grade 1 or higher 12 months after radiotherapy is lower in the group using extended vaginal dilation during radiotherapy (arm a). rates of vaginal stenosis of 50% have been observed in previous patient collectives and the investigators hypothesize that a reduction to 25% is possible in the experimental group.

the study is designed as a prospective, randomized, two-armed, single-center phase-ii-trial. 60 patients will be included in the study. patients fulfilling the inclusion criteria will be randomized into one of the two arms, which differ only in the diameter of a tampon used for vaginal dilatation during treatment. all patients will receive standard (chemo)radiotherapy with a total dose of 45-50,4 gy (single dose 1,8-2 gy) to the pelvic and inguinal (if required) lymphatic drainage with a boost to the anal canal up to 54-60 gy (single doses 1.8-2.2 gy). the primary objective is the assessment of the incidence and grade of vaginal fibrosis 12 months after (chemo)radiotherapy for anal cancer depending on the extent of intrafractional vaginal dilatation. secondary endpoints are clinical symptoms and toxicity according to the common toxicity criteria (ctc) version 5.0, assessment of clinical feasibility of daily use of a tampon for vaginal dilatation, assessment of the compliance for the use of a vaginal dilatator and quality of life assessed with the eortc-qlq30/-anl27 questionnaires.

Eligibility criteria:
inclusion criteria: * female patient * histologically confirmed squamous anal cancer * indication for definitive or postoperative radiotherapy * ecog 0-2 * age \> 18 years * written informed consent exclusion criteria: * patients refusal or incapability of informed consent * no vaginal dilatation possible prior to radiation treatment start * prior pelvic irradiation (if direct field border or even overlap of radiation fields assumed) * participation in another clinical trial which might influence the results of the dilana trial * pregnancy/nursing period or inadequate contraception in women with child bearing potential

Keywords: female patients quality of life vaginal dilator vaginal fibrosis
pct reveals good recovery after acute diverticulitis: the pregrad study

Conditions: Acute Diverticulitis

Summary: diverticular disease is a common disease in developed countries, affecting 2.5 million individuals in the united states (us). prevalence of diverticula increases with age and goes up to 50 to 66% in patients older than age 80 years. approximately 10 to 25% of patients with diverticulosis will develop diverticulitis. acute diverticulitis (ad) accounts for 312,000 admissions and 1.5 million days of inpatient care in the us, where its annual treatment costs exceed 2.6 billion dollars. with the ageing of global population these numbers are expected to rise. procalcitonin (pct) is a biomarker widely used to monitor bacterial infections and guide antibiotic therapy in intensive care units and has been shown to be useful in different surgical fields such as acute appendicitis. recently, has been demonstrated that pct and cpr have good predictive value of anastomotic leak (al) after colorectal surgery. a multicentric study has been designed to test if pct, crp and wbc values might be able to predict the outcomes of patients admitted in emergency setting for acute diverticulitis. in particular if they might distinguish between patients needing only conservative (nothing per os, iv fluids and antibiotics) or interventional therapy such as radiological drain or even surgery, in the aim to optimize and individualize each patients therapy and speed patients discharge.


Eligibility criteria:
inclusion criteria: * all patients admitted for acute diverticulitis in emergency setting * with ct scan performed and hinchey \> or = 2 exclusion criteria: * age \< 18 years * pregnant women * patients with acute diverticulitis without ct scan * patients with acute diverticulitis with hinchey i
virtual reality exposure therapy for speech anxiety using commercial hardware and software

Conditions: Social Phobia; Anxiety; Behavior Therapy

Summary: virtual reality exposure therapy (vret) is an efficacious treatment of fear and anxiety, but because of the high financial costs and technical complexity of the past generation of vr hardware, there has been no large-scale implementation of this promising treatment. the present study will investigate whether off-the-shelf, commercial vr hardware and software can be used as stimuli material to conduct in-session exposure therapy for speech anxiety. the study will recruit n=25+25 participants from the general public suffering from substantial speech anxiety, who will be randomized to either a waiting-list, or one-session vret with a therapist, followed by four weeks of a progressive maintenance program encouraging in-vivo exposure. the waiting-list group will then receive an internet-delivered vret treatment program.


Eligibility criteria:
inclusion criteria: * substantial public speaking anxiety * have access to vr-compatible smartphone (including internet) * can travel to stockholm university for treatment on one occasion * can speak and understand sufficient swedish exclusion criteria: * deficits in sight or balance impacting the vr-experience * a severe psychiatric disorder better treated elsewhere, including current major depression, alcohol or drug abuse, bipolarity, psychosis or similar * active psychopharmacological treatment, unless stable for last 3 months * other ongoing psychological treatment
stories for change: digital storytelling as a tool for engagement in facilitated discussion for diabetes

Conditions: Diabetes Mellitus

Summary: racial and ethnic minorities with type ii diabetes in the us are more likely to develop complications and die from the disease than the general population. the foreign-born subset of this population is less likely to adhere to diabetes care recommendations than us-born patients, thereby placing them at higher risk for complications. in our previous pilot project, eight stories were assessed through preliminary multi-site intervention for acceptability and efficacy in diabetes management among latino and somali patients with poorly controlled type ii diabetes. the goal of this project is to evaluate a new format for delivery of a culturally tailored digital storytelling intervention by incorporating a facilitated group discussion following the videos, for management of type ii diabetes in latino communities.


Eligibility criteria:
inclusion criteria: 1. self-identify as hispanic/latino 2. are spanish-speaking 3. receive primary care at one of the participating clinical sites 4. self-reported diagnosis of type ii diabetes exclusion criteria: 1. not able to give informed consent 2. not able to participate in a group discussion
metrological characteristics of the inertial unit "fox hikob©" in comparison with the reference system for the adaptive trigger system "functional electrical stimulation" of foot elevators in hemiplegic post-stroke patients

Conditions: Stroke

Summary: the main objective of this study is to evaluate the metrological characteristics of the data processing algorithms from inertial sensors (fox © hikob) for the reconstruction of movement relative to the reference system (vicon) for measurement of dorsiflexion at the beginning of a step and in the middle of the oscillating phase.

the secondary objectives of this study are: 1. / - to assess the metrological characteristics of the data from inertial sensors (fox © hikob) for the reconstruction of the movement in comparison with reference systems (gaitrite or zebris systems, vicon) in terms of: a. ability to determine the walking speed, stride length, the acceleration of plantar flexion at the beginning of the weight-bearing phase b. ability to objectify performance reduction during a 6 minute test. c. ability to identify different types of movement: simple walking, turn, obstacle clearance, staircase. 2. / - to analyze the emg signal upon voluntary dorsiflexion of the foot of the paretic side from a sitting position before and after a fatigue test (objective d)

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * stroke, ischemic or hemorrhagic, supra-tentorial, regardless of the post-stroke period * the patient can walk 10m without human help, with or without a cane and has a foot elevator deficit requiring the use of technical assistance or causing a walking defect exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient or his/her representative refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant or breastfeeding * the patient has cognitive impairment * presence of permanent plantar flexion of the ankle joint with ankle dorsiflexion, knee straight, lower than 0°. * uncontrolled epilepsy
a study to assess the long- term safety of tc-5214 as an adjunct therapy in patients with major depressive disorder

Conditions: Major Depressive Disorder; MDD; Depression

Summary: the purpose of this study is to determine if tc-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant medicine.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent before initiation of any study-related procedures. * the patient must have a clinical diagnosis of major depressive disorder (mdd) with inadequate response to no more than one antidepressant. * outpatient status at enrollment and randomization. exclusion criteria: * patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder. * patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide. * patients with significant liver, kidney, lung, heart, neurological, or any other medical conditions that might confound the study or put the patient at greater risk during study participation.

Keywords: major depressive disorder mdd depression safety add-on therapy
in-hospital versus after-discharge complete revascularization

Conditions: STEMI - ST Elevation Myocardial Infarction; Multivessel Coronary Artery Disease

Summary: patients with stemi and multivessel disease in whom the culprit lesion has been successfully revascularized during prmimary pci, will be randomized to in-hospital or after-discharge complete revascularization. the purpose of this study is to evaluate the impact of these two different strategies in terms of hospital stay.

stemi patients with mutivessel disease are, after successful primary angioplasty, randomized 1:1 ratio to either in-hospital complete revascularization or after-discharge complete revascularization strategy. eligible non-culprit coronary arteries must be \>2.0 mm in diameter and at the discretion of the operator suitable for pci. only arteries with angiographically stenoses ≥70% or between ≥50% and \<70 in proximal segments can be randomized. patients in the in-hospital revascularization group will undergo to non-culprit percutaneous coronary intervention (pci) at least 24 hours after st-segment elevation myocardial infarction. on the other hand, patients in the after-discharge group will undergo to non-culprit pci within 4-6 weeks after stemi.

Eligibility criteria:
inclusion criteria: * acute onset of chest pain \<12 hours duration. * st-segment elevation ≥ 0.1 millivolt in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block. * culprit lesion in a major native vessel, with successful primary pci. * presence of at least one non-culprit lesion more than or equal to 70% of stenosis in a vessel more than 2mm of diameter or more than or equal to 50% stenosis in proximal segments. * the patient is able to give written consent for participation in the study. exclusion criteria: * pregnancy. * significant left main stenosis. * stent thrombosis. * chronic total occlusion. * severe stenosis of non-culprit vessels with distal flow less than timi3. * significant non-culprit stenosis no candidate to revascularization. * presence of valvulopathy candidate for cardiac surgery. * cardiogenic shock status at admission. * the patient is not able to give written consent for participation in the study.

Keywords: stemi multivessel pci
cisgender female patients who start on long acting cabotegravir for prep

Conditions: Hiv

Summary: oral prep regimens (ftc/tdf have been the mainstay of hiv prevention however patients now have more options for hiv prevention. in addition to oral prep regimens, the fda approved the use of long acting cabotegravir (cab-la) as the first long-acting medication for hiv prevention. this study will evaluate real world clinical outcomes of cisgender female patients who start cab-la for prep.


Eligibility criteria:
inclusion criteria: 1. cisgender females, ages 18 years and older 2. negative hiv test at baseline 3. negative pregnancy test at baseline 4. weigh at least 35 kilograms 5. already prescribed cab-la (apretude) exclusion criteria: 1. transgender females or males 2. cisgender males 3. cisgender female who is actively breastfeeding 4. severe hepatotoxicity 5. evidence of hepatitis b infection 6. history or presence of allergies to cabotegravir or its components
cranberry juice for treatment of urinary tract infections

Conditions: Urinary Tract Infections

Summary: the purpose of this study is to determine whether daily consumption of cranberry juice lessens the symptoms and prevents the recurrence of urinary tract infections (utis). this study will also determine whether drinking cranberry juice for 6 months selects for less virulent bacteria in the rectal, vaginal, and urethral areas.

participants in this study will be randomly assigned to consume either 8 ounces of cranberry juice or placebo juice twice a day for 6 months. participants will have follow-up visits at 3 and 6 months, and whenever they experience a symptomatic episode. urine, vaginal and rectal specimens will be taken at each visit to test for the presence of bacteria that cause urinary tract infections. participants will complete a questionnaire at study entry, day 3, weeks 1 and 2, and monthly thereafter or whenever there is a recurrence of symptoms.

Eligibility criteria:
inclusion criteria: * culture-confirmed urinary tract infection at study start exclusion criteria: * other chronic disease * antibiotics within 48 hours prior to study start * hospitalization for any reason within 2 weeks prior to study start * stones in urinary tract * plans to leave ann arbor within 6 months after study start * allergy to cranberry or cranberry compounds * pregnancy

Keywords: vaccinium macrocarpon
tradeoffs in patient decision making about rectal cancer treatment: benefits compared to quality of life.

Conditions: Patient Preference

Summary: this study is aiming to look into patients' treatment preferences and their socio economic background as well as the exploration of thought processes leading to these preferences. it will integrate, in two exploratory questionnaires, the three most common treatment schema (standard of care, non-operative management, surgery alone) all of which have been demonstrated efficacious.

the primary study objective is to evaluate socioeconomic and demographic factors involved in patients' / physicians treatment preferences. the secondary objective is to assess the tradeoff level between the benefits versus quality of life. this study will evaluate 192 participants: 14 physicians (group a) and 178 patients (group b). participants with operable rectal cancer or health professionals will be screened for eligibility. subsequently, these participants will be offered to participate in this pilot study and provided a consent form. when a participant has consented to participate, he/she will be provided with a first questionnaire (socio-demographic characteristics, some clinical data and medical baseline information as well as details about their current knowledge about treatments). an informational brochure will be given after answering the first questionnaire describing different treatment regimens, treatment duration, potential side effects and oncologic outcomes. a second questionnaire will be provided (evaluating patients treatment preferences and tradeoff). the consent form, brochure and questionnaires will be available only in an electronic format (microsoft form).

Eligibility criteria:
inclusion criteria: group a * new rectal cancer patient * operable patients * capable adults older than 18 years of age * capacity to sign a consent form * capacity to answer questionnaires on an online platform group b * treating physician specialists * capacity to sign a consent form * capacity to answer questionnaires on an online platform exclusion criteria: group a: * patient unable to sign a consent form * patients with metastasis * recurrent tumours * inability to answer questionnaires on an online platform * inability to communicate in french or english group b: * participant unable to sign a consent form * inability to answer questionnaires on an online platform

Keywords: colorectal cancer treatment preferences
preoperative hyperthermia in major abdominal surgery patients

Conditions: Colon Cancer

Summary: the investigators hypothesize that preoperative hyperthermia improves postoperative complications and compare a placebo group with standard thermoregulatory management (normothermia) to a treatment group receiving 2,5 hours of hyperthermia (38.5-39.5 °c core temperature) in a randomized, single blinded, controlled trial.

the investigators hypothesize that preoperative hyperthermia improves postoperative complications and compare a placebo group with standard thermoregulatory management (normothermia) to a treatment group receiving 2,5 hours of hyperthermia (38.5-39.5 °c core temperature) in a randomized, single blinded, controlled trial.

Eligibility criteria:
inclusion criteria: * male and female patients, age 18 - 75 * open abdominal, curative cancer surgery \> 2 h exclusion criteria: * pregnancy * chronic cortisone treatment * ongoing chemotherapy * acute infections, septic surgery * palliative surgery (e.g. debulking only)
my type 2 diabetes: person-centred health care

Conditions: Diabetes Mellitus, Type 2

Summary: the type 2 diabetes (t2d) project is a research and innovation project that will create a new comprehensive, participant-centered service model for interaction, increased physical activity, self-management, distance monitoring and lifestyle change for patients with type 2 diabetes. central to the degree of innovation is a new model for interaction and use of technology for distance monitoring and coping.

type 2 diabetes is both physically and mentally stressful. at the same time, it requires a high individual effort, which can be demanding. good mental health is necessary to be able to manage and control diabetes in a healthy and effective way. therefore, we want to create an offer that takes care of the whole person, and physically as well as mentally. personal follow-up based on surveys and conversations, the study participant and a contact person will prepare a 12-week plan that will be implemented with self-measurements and follow-up from the contact person. the plan will consist of the activities that best suit the participant's needs. it can be physical activity, diet course, health competence, motivation and psychosocial intervention that will be useful for the participant. after 12 weeks, the implementation will be evaluated. several new technological solutions are developed and will be used during the project period. a digital tool for mapping of the individuals needs will be an important part of the survey that is done during start-up. activity clocks will be used for measuring steps, heart rate, and number of personalized activity index (pai). an online portal for communication and interaction will make information easily accessible to users, simplify distance follow-up and communication flow. the intervention will take place at two healthy life centres. a healthy life centre is an interdisciplinary primary health care service which offers effective, knowledge-based measures for people with, or in high risk of disease, who need support in health behaviour change and in coping health problems and chronic disease. the healthy life centre is part of the public health care service in the municipality. healthy life centre programs have a patient centred approach and aim at strengthening the individual's control of his or her own health. the intervention study starts in two municipalities in møre og romsdal, and the goal is to make the offer national.

Eligibility criteria:
inclusion criteria: • type 2 diabetes exclusion criteria: * unstable cardiovascular disease * severe chronic obstructive pulmonary disease (copd)